Intra-Cellular Therapies Inc. (NASDAQ:ITCI) has received a consensus rating of “Hold” from the nine analysts that are presently covering the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $39.83.
ITCI has been the topic of several recent research reports. Piper Jaffray Cos. restated an “overweight” rating and set a $57.00 target price on shares of Intra-Cellular Therapies in a report on Tuesday, September 13th. Royal Bank Of Canada lowered their target price on Intra-Cellular Therapies from $74.00 to $49.00 and set an “outperform” rating on the stock in a report on Thursday, September 29th. Zacks Investment Research cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Wednesday, October 19th. Cowen and Company restated a “buy” rating and set a $75.00 target price on shares of Intra-Cellular Therapies in a report on Friday, August 5th. Finally, JMP Securities lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 29th.
In other news, Director Christopher D. Alafi bought 34,000 shares of the business’s stock in a transaction on Monday, November 14th. The shares were bought at an average price of $14.50 per share, with a total value of $493,000.00. Following the completion of the transaction, the director now directly owns 730,529 shares in the company, valued at $10,592,670.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.80% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in ITCI. Price T Rowe Associates Inc. MD raised its stake in shares of Intra-Cellular Therapies by 5,767.6% in the third quarter. Price T Rowe Associates Inc. MD now owns 563,702 shares of the biopharmaceutical company’s stock worth $8,591,000 after buying an additional 554,095 shares during the last quarter. Credit Suisse AG raised its stake in shares of Intra-Cellular Therapies by 3.9% in the third quarter. Credit Suisse AG now owns 28,001 shares of the biopharmaceutical company’s stock worth $426,000 after buying an additional 1,058 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $9,284,000. Hillhouse Capital Management Ltd. purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $15,240,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $342,000. 67.13% of the stock is currently owned by institutional investors.
Intra-Cellular Therapies (NASDAQ:ITCI) opened at 13.66 on Tuesday. The company’s market cap is $591.04 million. Intra-Cellular Therapies has a 52 week low of $10.80 and a 52 week high of $59.76. The company has a 50-day moving average price of $13.23 and a 200 day moving average price of $32.05.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.14. The company had revenue of $4.36 million for the quarter, compared to analyst estimates of $0.04 million. The company’s revenue for the quarter was up NaN% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.91) earnings per share. On average, equities research analysts forecast that Intra-Cellular Therapies will post ($2.84) EPS for the current fiscal year.